A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies.

被引：0

作者：

Neelapu, Sattva Swarup

Hamadani, Mehdi

Miklos, David Bernard

Holmes, Houston

Hinkle, John

Kennedy-Wilde, Jackie

Maller, Ori

Weinstein, Maggie

Galimi, Francesco

Lai, Rose

Stevens, Don A.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[2] Med Coll Wisconsin, BMT Cellular Therapy Program, Milwaukee, WI USA

[3] Stanford Univ, Sch Med, Stanford, CA USA

[4] Texas Oncol, Dallas, TX USA

[5] EarlyPhase Sci Inc, Austin, TX USA

[6] Adicet Bio, Menlo Pk, CA USA

[7] Norton Canc Inst, Louisville, KY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7509

引用

页数：1